DHR Add to watchlist
$200.79 +1.74 (+0.87%)
After Hours: $200.79 +0.00 (+0.00%)
Last updated: Jul 15, 2026 22:10
52-Week Range
$200.79
$160.93 $200.79 $242.80

Fundamentals Overview

Danaher Corporation is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 38.7 P/B 2.68 P/S 5.74

Intrinsic value (DCF)

+8.1% upside vs price

Profitability

Net margin 14.9%

Risk (Beta)

0.82 — in line vol

Earnings & growth

EPS $5.19 Rev -13% Profit -14% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 51% confidence Risk: Moderate Volatility — Beta 0.82. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: B+

Pressures (Sell):

Sentiment weakening (2 downgrades) · 3M vs S&P 500: -7.5%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$142.11B
P/E (TTM)
38.71
EPS (TTM)
$5.19
Dividend Yield
0.72%
52-Week Range
$160.93 - $242.80
Volume vs Avg
N/A
Beta
0.82

About

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific resea...
Sector: Healthcare
Headquarters: US
Employees: 61,000
IPO Date: Dec 1978
Beta: 0.82 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 11, Equal Weight: 4, Neutral: 3, Outperform: 7, Overweight: 4, Sector Outperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $217.06; current price is $200.79. That’s a +8.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 38.71
DCF value (model) $217.06 (8.1% upside)
PEG (TTM) N/A
P/B (TTM) 2.68
P/S (TTM) 5.74
P/FCF (TTM) 26.86
Liquidity & enterprise
Current Ratio (TTM) 1.87
Quick Ratio (TTM) 1.52
Cash Ratio (TTM) 0.76
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 14.89%
Gross margin (TTM) 60.68%
Operating margin (TTM) 20.95%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for DHR.

Analyst Sentiment at a Glance

B+ Sentiment Weakening
Buy 11Equal Weight 4Neutral 3Outperform 7Overweight 4Sector Outperform 1
1 upgrade, 2 downgrades
Price Target Consensus
Current $200.79
Median $230.00
Consensus $223.63
Low consensus $200.00
High consensus $249.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Evercore ISI Group maintain Outperform Outperform 2026-07-06
Piper Sandler maintain Neutral Neutral 2026-06-11
HSBC maintain Buy Buy 2026-06-03
Citigroup downgrade Buy Neutral 2026-05-27
Morgan Stanley maintain Overweight Overweight 2026-04-23
Wells Fargo maintain Equal Weight Equal Weight 2026-04-22
Guggenheim maintain Buy Buy 2026-04-22
Baird maintain Outperform Outperform 2026-04-22
UBS maintain Buy Buy 2026-04-22
Baird maintain Outperform Outperform 2026-04-17
Barclays maintain Overweight Overweight 2026-04-14
Goldman Sachs maintain Buy Buy 2026-04-13
Evercore ISI Group maintain Outperform Outperform 2026-04-06
Jefferies maintain Buy Buy 2026-01-29
JP Morgan maintain Overweight Overweight 2026-01-29
TD Cowen maintain Buy Buy 2026-01-07
Guggenheim maintain Buy Buy 2026-01-05
Wells Fargo maintain Equal Weight Equal Weight 2025-12-15
Wells Fargo maintain Equal Weight Equal Weight 2025-10-23
TD Cowen maintain Buy Buy 2025-10-22
Barclays maintain Overweight Overweight 2025-10-22
Rothschild & Co downgrade Buy Neutral 2025-10-08
Evercore ISI Group maintain Outperform Outperform 2025-10-07
B of A Securities maintain Buy Buy 2025-09-22
Guggenheim maintain Buy Buy 2025-07-23
Baird maintain Outperform Outperform 2025-07-23
Wells Fargo maintain Equal Weight Equal Weight 2025-07-23
UBS maintain Buy Buy 2025-07-23
Baird maintain Outperform Outperform 2025-07-18
Scotiabank upgrade Sector Perform Sector Outperform 2025-07-11